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Abstract. 
 
Exposure for 24 h of mucus-secreting HT-29 
cells to the sugar analogue GalNAc-
 
a
 
-
 
O
 
-benzyl results 
in inhibition of Gal
 
b
 
1-3GalNAc:
 
a
 
2,3-sialyltransferase, 
reduced mucin sialylation, and inhibition of their secre-
tion (Huet, G., I. Kim, C. de Bolos, J.M. Loguidice, O. 
Moreau, B. Hémon, C. Richet, P. Delannoy, F.X. Real., 
and P. Degand. 1995. 
 
J. Cell Sci.
 
 108:1275–1285). To de-
termine the effects of prolonged inhibition of sialyla-
tion, differentiated HT-29 populations were grown un-
der permanent exposure to GalNAc-
 
a
 
-
 
O
 
-benzyl. This 
results in not only inhibition of mucus secretion, but 
also in a dramatic swelling of the cells and the accumu-
lation in intracytoplasmic vesicles of brush border–asso-
ciated glycoproteins like dipeptidylpeptidase-IV, the 
mucin-like glycoprotein MUC1, and carcinoembryonic 
antigen which are no longer expressed at the apical 
membrane. The block occurs beyond the 
 
cis
 
-Golgi as 
substantiated by endoglycosidase treatment and bio-
synthesis analysis. In contrast, the polarized expression 
of the basolateral glycoprotein GP 120 is not modified. 
Underlying these effects we found that (
 
a
 
) like in mu-
cins, NeuAc
 
a
 
2-3Gal-R is expressed in the terminal po-
sition of the oligosaccharide species associated with the 
apical, but not the basolateral glycoproteins of the cells, 
and (
 
b
 
) treatment with GalNAc-
 
a
 
-
 
O
 
-benzyl results in 
an impairment of their sialylation. These effects are re-
versible upon removal of the drug. It is suggested that 
 
a
 
2-3 sialylation is involved in apical targeting of brush 
border membrane glycoproteins and mucus secretion in 
HT-29 cells.
 
E
 
nterocytic
 
 and mucus-secreting populations iso-
lated from the human colon carcinoma cell line
HT-29 have proven extremely useful for the study
 
of intestinal cell differentiation (for review see
 
 
 
Zweibaum
et al., 1991). The differentiated populations used in this
study were isolated from the mainly undifferentiated pa-
rental line (Fogh and Trempe, 1975) by selection with in-
creasing concentrations of methotrexate (MTX)
 
1
 
 (Lesuf-
 
fleur et al., 1990, 1991). Cells selected with 10
 
2
 
6
 
 and 10
 
2
 
5
 
M MTX form a homogeneous population of mucus-secret-
ing cells (Lesuffleur et al., 1990, 1991), whereas selection
with 10
 
2
 
3
 
 M MTX results in a population of enterocytic
phenotype (Lesuffleur et al., 1991). Whatever their pheno-
type, these populations share common differentiation char-
acteristics, namely (
 
a
 
) a postmitotic onset of the differenti-
ation process and (
 
b
 
) a polarized organization of the cell
monolayer with the presence of an apical brush border en-
dowed with several glycoproteins such as dipeptidylpepti-
dase-IV (DPP-IV), the carcinoembryonic antigen (CEA)
and the mucin-like glycoprotein MUC1. Mucus-secreting
cell populations selected by MTX have been extensively
analyzed as to the characteristics of their mucins: at the
mRNA level they mainly express MUC5AC (Lesuffleur et
al., 1993, 1995); at the protein level they secrete mucus of
gastric immunoreactivity (Lesuffleur et al., 1990) with a
main oligosaccharide species similar to the clone HT29-
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1.
 
Abbreviations used in this paper
 
: CEA, carcinoembryonic antigen;
DPP-IV, dipeptidylpeptidase-IV; GalNAc-
 
a
 
-
 
O
 
-benzyl, benzyl-2-aceta-
mido-2-deoxy-
 
a
 
-
 
d
 
-galactopyranoside; MAA, 
 
Maackia amurensis
 
 aggluti-
nin; MTX, methotrexate; PNA, 
 
Arachis hypogaea
 
 agglutinin; SNA, 
 
Sam-
bucus nigra
 
 agglutinin. The abbreviations for sialyltransferases are
according to the new systematic nomenclature proposed by Tsuji et al.
(1996).
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16E (Capon et al., 1992), NeuAc
 
a
 
2-3Gal
 
b
 
1-3GalNAc-
 
R
 
(sialyl T antigen) (Lesuffleur et al., 1993; Huet et al.,
1995).
Previous results have shown that short-term (24-h) ex-
posure of postconfluent mucus-secreting HT-29 cells to
benzyl-2-acetamido-2-deoxy-
 
a
 
-
 
d
 
-galactopyranoside (Gal-
NAc-
 
a
 
-
 
O
 
-benzyl), an inhibitor of mucin 
 
O
 
-glycosylation
(Kuan et al., 1989; Huang et al., 1992; Byrd et al., 1995), re-
sults in a decrease of mucus secretion, a lower sialic acid
content of newly synthesized mucins, and an increased
content of T antigen (Gal
 
b
 
1-3GalNAc-
 
R
 
) (Huet et al.,
1995). Similar effects of GalNAc-
 
a
 
-
 
O
 
-benzyl have been
demonstrated in LS174-T colon cancer cells (Kuan et al.,
1989) or KATO III gastric cells (Byrd et al., 1995). In the
case of HT-29 cells, the change in mucin glycosylation has
been shown to be a consequence of the metabolization
of GalNAc-
 
a
 
-
 
O
 
-benzyl into Gal
 
b
 
1-3GalNAc-
 
a
 
-
 
O
 
-benzyl
which, in turn, is a potent competitive inhibitor of the
Gal
 
b
 
1-3GalNAc 
 
a
 
2,3-sialyltransferase (Huet et al., 1995;
Delannoy et al., 1996), the main sialyltransferase activity
expressed in HT-29 cells (Majuri et al., 1995; Delannoy et al.,
1996).
Because 
 
O
 
-glycosylation may be part of the processing
of a wide variety of proteins and the biochemical changes
observed after 24 h of treatment may not fully reflect the
activity of GalNAc-
 
a
 
-
 
O
 
-benzyl, we set to analyze the ef-
fects of a permanent exposure to this drug on the prolifer-
ation and differentiation of mucus-secreting HT-29 cells.
We found that, in addition to an inhibition of mucus secre-
tion, apical glycoproteins such as the transmembrane gly-
coprotein MUC1 (Gendler et al., 1987), as well as the
 
N
 
-glycosylated proteins DPP-IV (Semenza, 1989; Misumi et
al., 1992) and CEA (Fukushima et al., 1995)
 
 
 
considerably
accumulate within the cytoplasm and are no longer ex-
pressed at the apical membrane, this occurring without
modification of the polarization of the cells. Based on this
observation we further found that, like in mucins,
NeuAc
 
a
 
2-3 is the main sialylated determinant associated
with DPP-IV, MUC1, and CEA in differentiated HT-29
cells, whether of mucus-secreting or enterocytic pheno-
type, and that treatment with GalNAc-
 
a
 
-
 
O
 
-benzyl results
in a decreased sialylation of these proteins. These effects
of GalNAc-
 
a
 
-
 
O
 
-benzyl are rapidly reversible upon re-
moval of the drug. These results raise the question of
whether, in differentiated HT-29 cells, 
 
a
 
2-3 sialylation is
required for mucus secretion as well as for the correct tar-
geting of apical glycoproteins.
 
Materials and Methods
 
Cell Culture
 
HT-29–differentiated subpopulations were derived from the original cell
line (Fogh and Trempe, 1975) that was obtained from the late J. Fogh
(Sloan-Kettering Memorial Cancer Center, Rye, NY). The cells adapted
to MTX 10
 
2
 
6
 
, 10
 
2
 
5
 
, and 10
 
2
 
3 
 
M (Lesuffleur et al., 1990, 1991) were used
after several weekly passages of reversion to drug-free medium (10–40
passages) and are referred to as HT29-RevMTX10
 
2
 
6
 
, RevMTX10
 
2
 
5
 
 (mu-
cus-secreting cells), and RevMTX10
 
2
 
3 
 
(enterocytic cells).
 
 
 
Cells were
grown in DME (Life Technologies, Inc., Cergy-Pontoise, France) supple-
mented with 10% inactivated FBS for 30 min at 56
 
8
 
C (Boehringer Mann-
heim Biochemicals, Mannheim, Germany). GalNAc-
 
a
 
-
 
O
 
-benzyl (Sigma
Chemical Co., St. Louis, MO) was solubilized in DME. All experiments
and maintenance of the cells were done in 25- or 75-cm
 
2
 
 T flasks (Corning
Glass Works, Corning, NY), and in 24-well cell culture clusters (Costar,
Cambridge, MA) at 37
 
8
 
C in a 10% CO
 
2
 
 / 90% air atmosphere. Cells were
seeded at 2 
 
3
 
 10
 
4
 
 cells/cm
 
2
 
. The same conditions were applied to cells
grown on tissue culture-treated Transwell polycarbonate membranes with
a 24.5-mm diam and a 0.4-
 
m
 
m pore size (Costar). For maintenance pur-
poses, cells were passaged weekly, using 0.025% trypsin in 0.53 mM
EDTA in PBS Ca
 
2
 
1
 
Mg
 
2
 
1
 
-free (PBS
 
2
 
). The medium was changed daily in
all culture conditions. For growth curves, cells grown in 24-well culture
clusters were detached with trypsin and counted with a hemocytometer.
Cell volume was determined in a hematocrit. Control Caco-2 cells were
cultured as previously reported (Pinto et al., 1983) and analyzed between
passages 70 and 80.
 
Antibodies and Lectins
 
Mouse mAbs HBB 3/775/42 (Hauri et al., 1985) and G1/136 (Eilers et al.,
1989) specific for human DPP-IV and a 120-kD basolateral glycoprotein
respectively, were a gift of H.P. Hauri (Biocenter of the University of
Basel, Basel, Switzerland). Rat mAb 4H3 against human DPP-IV (Gorvel
et al., 1991) was obtained from S. Maroux (CNRS Unité de Recherche
Associee 1820, Faculté des Sciences de Saint Jerôme, Marseille, France).
Mouse mAb 517 (Le Bivic et al., 1988) against CEA was obtained from A.
Le Bivic (Faculté des Sciences de Luminy, Marseille, France). Mouse
mAb BC-2 (Xing et al., 1989), which recognizes a sequence in the tandem
repeat of the MUC1 gene product was obtained from I. McKenzie (Austin
Cancer Research Institute, Heidelberg, Victoria, Australia). Mouse mAb
B72.3 against sialyl-Tn (Nuti et al., 1982) was obtained from K.O. Lloyd
(Memorial Sloan-Kettering Cancer Center, New York). Mouse mAb
TS2/16 against the integrin 
 
b
 
1 subunit (Arroyo et al., 1992) was obtained
from F. Sanchez-Madrid (Universidad Autónoma de Madrid, Madrid,
Spain). Rabbit polyclonal Abs against porcine villin (Robine et al., 1985)
and the tight junction protein ZO-1 (Willot et al., 1992) were obtained
from D. Louvard (Institut Curie, Paris, France) and J.M. Anderson (Yale
University, New Haven, CT), respectively. For the detection of gastric
mucins we used the same rabbit polyclonal Ab L56/C as previously used
for cloning the L31 mucin cDNA encoding the 3
 
9
 
 end of MUC5AC
(Lesuffleur et al., 1995). Fluorescein-conjugated 
 
Maackia amurensis 
 
ag-
glutinin (MAA) (Wang and Cummings, 1988), 
 
Sambucus nigra
 
 agglutinin
(SNA) (Shibuya et al., 1987), and Peanut (
 
Arachis hypogaea
 
) agglutinin
(PNA) (Lotan et al., 1975), which recognize the oligosaccharide species
NeuAc
 
a
 
2-3Gal-
 
R
 
, NeuAc
 
a
 
2-6Gal, and Gal
 
b
 
1-3GalNAc-
 
R,
 
 respectively,
were from Vector Labs Inc. (Burlingame, CA).
 
Immunofluorescence and Histochemical Staining
 
Indirect immunofluorescence was performed on cryostat sections of cell
layer rolls as reported (Lesuffleur et al., 1990). Briefly, late (day 21) cul-
tures of cells grown in 25-cm
 
2
 
 T flasks were rinsed with Ca
 
2
 
1
 
Mg
 
2
 
1
 
-free
PBS, the T flask was cut up with a soldering iron, and then the cell layer
gently was scraped with a rubber policeman and poured in a bath of liquid
nitrogen. The resulting frozen cell pellet was either stored in liquid nitro-
gen for further analysis, or immediately processed for cryostat sections.
This method has the double advantage of visualizing a large part of the
cell layer and allowing the concomitant detection of apical, basolateral,
and intracellular proteins on the same section. Double immunofluores-
cence was performed on sections postfixed with 3.7% paraformaldehyde
in PBS
 
2 
 
for 10 min at room temperature using secondary antibodies fluo-
rescein-coupled sheep anti–mouse or anti–rabbit Ig (Institut Pasteur Pro-
duction, Marne-la-Coquette, France) or rhodamine-coupled sheep anti-
globulins (Boehringer Mannheim Biochemicals). Desialylation was
performed by incubation for 16 h at 37°C of paraformaldehyde-fixed cryo-
stat sections with sialidase from 
 
Clostridium perfringens
 
 (Sigma Chemical
Co.) (50 mU/ml in 50 mM citrate buffer, pH 6.0, 0.9% NaCl, 0.1% CaCl
 
2
 
).
For confocal microscopy analysis, cells grown on glass coverslips were
fixed with 4% paraformaldehyde for 10 min, incubated with 50 mM
NH
 
4
 
Cl for 30 min, and then permeabilized with 0.1% saponin in 1% BSA/
PBS for 30 min. To detect 
 
b
 
1 integrin, mAb TS2/16 (0.5 
 
m
 
g/ml in 0.1% sa-
ponin in 1% BSA/PBS) was added for 1 h, followed by FITC-conjugated
goat anti–mouse; MAA (Vector Labs, Inc.) (20 
 
m
 
g/ml in 0.1% saponin in
Tris-HCl, pH 7.5, 15 mM KCl, 5 mM MgCl2) was added for 1 h, followed
by streptavidin-rhodamine (Pierce Chemical Co., Rockford, IL). Confocal
microscopy analysis was performed using a Leica instrument (model TCS
4D; St. Gallen., Switzerland). Histological staining with alcian blue, pH
2.5, and nuclear red was done on cryostat sections postfixed in absolute
ethanol for 10 min at room temperature.Huet et al. Blocking Effect of GalNAc-a-O-benzyl on Glycoprotein Traffic 1313
Transmission EM and
Ultrastructural Immunochemistry
Classical transmission EM was performed as previously reported (Lesuf-
fleur et al., 1990, 1991) on cells grown in 25-cm2 plastic flasks. Samples em-
bedded in Epon (Polysciences, Inc., Warington, PA) were reembedded to
make sections perpendicular to the bottom of the flask. Thin sections
were stained with toluidine blue. Ultrastructural immunochemistry was
performed as previously described (Hennebicq-Reig et al., 1996). After
rinsing three times in PBS, cells cultured in 25-cm2 flasks were fixed in
phosphate buffer containing 4% paraformaldehyde and 0.05% glutaralde-
hyde. The cell layer was scraped with a rubber policeman, the cell pellet
was infiltrated with phosphate buffer containing 2.3 M sucrose and 20%
polyvinylpyrolidone, and then frozen in liquid nitrogen. Ultrathin cryosec-
tions were successively incubated with PBS containing 10% FBS, mouse
mAb HBB 3/775/42 (DPP-IV), rabbit anti–mouse Ig antibody, and 8-nm
gold-conjugated protein A. All antibodies and gold-conjugated protein A
were diluted in PBS containing 10% FBS. The grids were finally counter-
stained with methylcellulose uranyl acetate and observed using an elec-
tron microscope (model 902; Carl Zeiss, Inc., Thornwood, NY). The same
procedure was applied for mAb 517 (CEA) and mAb BC-2 (MUC1).
Northern Blot Analysis
For detection of DPP-IV and villin mRNAs, total RNA was isolated from
the cells 16 h after medium change by lysis with guanidium isothiocyanate
and centrifugation through a CsCl gradient (Chirgwin et al., 1979). Sam-
ples of total RNA, denatured in 1 M glyoxal (Thomas, 1980), were frac-
tionated by electrophoresis through 1% agarose gels and then transferred
to nylon (model Hybond N; Amersham Corp., Amersham, UK) in the
presence of 203 SSC. Filters were incubated overnight at 428C in prehy-
bridization buffer containing 50% formamide, 53 SSC, 103 Denhardt’s
solution, 50 mM sodium phosphate, pH 6.5, and 250 mg/ml sonicated and
denatured salmon sperm DNA. Filters were then hybridized with the 32P-
labeled probe for 20 h at 428C in prehybridization buffer containing 10%
dextran sulfate (Thomas, 1980). Blots were washed twice with 23 SSC,
0.1% SDS at room temperature, once with 0.13 SSC, 0.1% SDS at 50°C,
and once, using the same solution, at 65°C for 15 min. Blots were then
processed for autoradiography. To normalize for RNA, filters were dehy-
bridized and stained with methylene blue. Methylene blue staining was
preferred to hybridization with actin or glyceraldehyde 3-phosphate dehy-
drogenase since it was found that the levels of these transcripts differ in di-
viding and postconfluent cells. DPP-IV was detected with cDNA DPI-101
(Darmoul et al., 1990) and villin with cDNA V19 (Pringault et al., 1986),
obtained from D. Louvard. The probe for human ST3Gal I (Kitagawa and
Paulson, 1994) was a 537-bp PCR-amplified fragment from HepG2 cells
cDNA corresponding to the coding region from nucleotide 361 to 898
(Recchi et al., 1998).
Measurement of Enzyme Activities
DPP-IV activity was measured in the cell homogenates as previously re-
ported (Lesuffleur et al., 1990), according to the method of Nagatsu et al.
(1976) using 1.5 mM glycyl-l-proline-4-nitroanilide as substrate. Results are
expressed as mU/mg of protein. One unit is defined as the activity that hy-
drolyzes 1 mmol of substrate/min at 378C. Proteins were measured with
the BCA protein assay reagent (Pierce Chemical Co.). Galbl-3GalNAc
a2,3-sialyltransferase activity was measured in cell homogenates prepared
by lysing the cells at 08C with 10 mM sodium cacodylate buffer, pH 6.5,
containing 1% Triton X-100 (Sigma Chemical Co.), 20% glycerol, 0.5 mM
dithiothreitol, and 5 mM MnCl2 (1 ml per 2.5 3 107 cells). After 10 min of
incubation under continuous stirring, cell homogenates were centrifuged
at 10,000 g for 15 min and the supernatants were used for enzymatic assay.
Protein concentration was determined according to Peterson (1977) using
BSA as standard. Cell homogenates (40 mg of protein) were brought to
a final volume of 120 ml with 0.1 M sodium cacodylate buffer, pH 6.5, 1%
Triton X-100, 0.1 M galactose (as inhibitor of b-galactosidase), 1 mM 2,3-
dehydro-2-deoxy-Neu5Ac (as inhibitor of sialidases), 52.9 mM CMP-[14C]-
Neu5Ac (0.58 GBq/mmol; 3.68 kBq/120 ml) (Amersham Corp.), containing
1 mM of Galbl-3GalNAca-O-pNp (Sigma Chemical Co.) and incubated
for 1 h at 378C. The reactions were stopped by adding 1 vol of ethanol.
Samples were centrifuged at 3,000 g for 5 min and then supernatants were
directly developed by descending paper chromatography with ethyl ace-
tate/pyridine/water (10:4:3 by vol) (Delannoy et al., 1993). Assays were
performed in duplicate. The rates of reactions were linear with time, at
least for 1 h. The incorporation of [14C]-Neu5Ac was determined by sub-
traction of the radioactivity measured in the absence of exogenous accep-
tors and results are expressed as average values in nmol of Neu5Ac trans-
ferred per milligram of protein and per hour.
Electrophoresis and Western Blotting
Cells were homogenized by sonication in Tris/Mannitol buffer. Immuno-
precipitation of DPP-IV, CEA, and MUC1 was performed as in Hauri et al.
(1985), using mAbs 3/775/42, 517, and BC-2 previously coated on protein
A–Sepharose beads (Pharmacia Fine Chemicals, Uppsala, Sweden). SDS-
PAGE was performed under reducing conditions on 4–20% gradient
polyacrylamide gels (Laemmli, 1970) either with 50 mg of total cellular
protein per lane or with DPP-IV, CEA, or MUC1 immunoprecipitates.
After electrophoresis, proteins were transferred to a nitrocellulose mem-
brane (model BioTrace NT; Gelman Sciences Inc., Ann Arbor, MI) as de-
scribed in Vaessen et al. (1981). The membranes were then treated for 2 h
with polyvinylpyrolidone K-30 (2% in TBS). Immunodetection of DPP-IV,
CEA, and MUC-1 was performed with mAbs 4H3, 517, and BC-2, respec-
tively, using secondary antibodies peroxidase-coupled anti-rat or anti-
mouse Ig accordingly (Biosys, Compiègne, France). For glycan detection,
membranes were incubated with digoxigenin-labeled lectins from Boeh-
ringer Mannheim Biochemicals at concentrations of 5 mg/ml in TBS for
MAA and SNA, and 2 mg/ml in TBS for PNA-digoxigenin. Then, the ni-
trocellulose membranes were incubated for 1 h with alkaline phosphatase-
labeled antidigoxigenin Fab fragments (1 mg/ml in TBS) (Boehringer
Mannheim Biochemicals). After washing, labeled glycoproteins were re-
vealed by 4-nitro blue tetrazolium chloride 5-bromo-4-chloro-3-indolyl-
phosphate staining. Desialylation was performed as for cryostat sections
before incubation with the digoxigenin-labeled lectins. Digestion with en-
doglycosidase H (Boehringer Mannheim Biochemicals) was carried out in
0.1 M phosphate buffer, pH 5.5, containing 0.02% SDS, 1% Triton X-100,
1% b-mercaptoethanol, 1 mM phenylmethylsulfonylfluoride, 10 mg/ml leu-
peptin, 10 mg/ml pepstatin, using 10 mU of endoglycosidase H overnight
at 378C. Digestion with endoglycosidase F/N-glycosidase F (Boehringer
Mannheim Biochemicals) was carried out in 0.1 M phosphate buffer, pH
7.0, containing 0.05% SDS, 1% Triton X-100, 1% b-mercaptoethanol, 1 mM
phenylmethylsulfonylfluoride, 10 mg/ml leupeptin, and 10 mg/ml pepstatin,
using 0.5 U of endoglycosidase F/N-glycosidase F overnight at 378C. Controls
were incubated in the same buffers overnight at 378C without glycosidase.
Metabolic Labeling and Immunoprecipitation
of DPP-IV
Cells were cultured in six-well plates with or without the presence of 2 mM
GalNAc-a-O-benzyl until day 11. Subsequently, untreated cells were
pulse labeled for 15 min with 200 mCi/well of [35S]-methionine (Amer-
sham Corp.) in 1 ml of methionine-free medium, and then chased for the
indicated periods of time with 1 ml 0.01 M methionine in regular medium.
The same protocol was applied to treated cells, except for the presence of
2 mM GalNAc-a-O-benzyl throughout the experiment. Cells were rinsed
in PBS and lysed in 1 ml of RIPA buffer (0.001 M Tris-HCl, pH 8.0, 0.01 M
NaCl, 0.1% SDS, 1% Triton X-100, 0.5% sodium deoxycholate, 1% phe-
nylmethylsulfonylfluoride, 0.001 M sodium ethylene diamine tetraace-
tate). Aliquots of 50 mg of proteins from cell lysates were incubated with
mAb 4H3 overnight at 48C. Immunocomplexes were collected on protein
G–Sepharose 4B (Sigma Chemical Co.), eluted in SDS sample buffer (0.2 M
Tris-HCl buffer, pH 6.8, containing 2% SDS and 30% glycerol) at 608C
for 5 min, and then analyzed on 5–30% SDS–polyacrylamide gels. For au-
toradiography, gels were fixed in 40% ethanol, 10% glycerol, 10% acetic
acid (by vol), soaked in Amplify (Amersham Corp.) for 20 min, dried on
Whatman paper, and then exposed to Cronex 4 NIF film (Dupont, Les
Ulis, France).
Results
GalNAc-a-O-benzyl Treatment Results in
a Dose-dependent Decrease of Mucus Secretion and 
Swelling of Mucus-secreting HT-29 Cells
To assay for a dose-dependent effect of GalNAc-a-O-ben-
zyl, mucus-secreting HT-29 cells (RevMTX1026) were
treated, from the day of seeding on, with different concen-The Journal of Cell Biology, Volume 141, 1998 1314
trations of the drug in the 0.1–2 mM range. Regardless of
the concentration used, no effect on cell viability was ob-
served, as assessed by the absence of cells in suspension
and trypan blue exclusion. As shown in Fig. 1, it has no ef-
fect on the doubling time of the cells in the first days in
culture, but results in a dose-dependent lower cell density
in the stationary phase. At the highest concentration (2 mM)
the cells stop growing before reaching total confluence,
with the cell layer occupying 75–80% of the surface of the
flask (Fig. 1). This effect is associated with a dramatic
swelling of the cells (Figs. 1 and 2), with their cytoplasm
appearing filled with a honeycomb-like accumulation of
vesicles of various sizes during transmission electron mi-
croscopy (see Fig. 4 c). Concomitant with these changes,
the mucus gel is totally absent from the cells treated with
the highest concentrations, even when the cells are main-
tained for a longer period (,30 d). The decrease in mucus
content was further demonstrated by the analysis of sec-
tions of the cell layer (Fig. 2). At the highest concentration
(2 mM), there was a total absence of alcian blue–stained
material (Fig. 2 e). In addition, the dense immunofluores-
cent staining of apical mucus droplets observed in control
cells with antigastric mucus antibodies was no longer ob-
served in cells treated with 2 mM, having been replaced by
a diffuse staining of the cytoplasm (Fig. 2 f).
Treatment of Mucus-secreting HT-29
Cells with GalNAc-a-O-benzyl Leads to an 
Intracytoplasmic Accumulation of Brush Border 
Membrane–associated Glycoproteins
Because the most clear-cut effect of GalNAc-a-O-benzyl
was observed at 2 mM, all further experiments were done
at this concentration. In control postconfluent HT29-
RevMTX1026 cells, DPP-IV, MUC1, and CEA are exclu-
sively associated with the apical brush border of the cells,
as previously reported (Lesuffleur et al., 1993) and shown
in Fig. 3, g, i, and k. In contrast, in GalNAc-a-O-benzyl–
treated cells, DPP-IV, MUC1, and CEA are present in the
totality of the cytoplasm (Fig. 3, h, j, and l); this occurs
without modification of the morphological polarity of the
cells, substantiated by the apical expression of villin and
ZO1 (Fig. 3, a–d). Interestingly, and in contrast to what
observed for apical glycoproteins, the treatment had no ef-
fect on the basolateral expression of GP120 (Fig. 3, e and
f). The cytoplasmic accumulation of apical glycoproteins
in treated cells was further confirmed using immunoelec-
tron microscopy: unlike in control cells where they are re-
stricted to the apical brush border, DPP-IV, MUC1, and
CEA are localized in the numerous vesicles that fill the cy-
toplasm (Fig. 4). Using DPP-IV as a marker of the effect,
we further found that this altered distribution is associated
with an increased level of expression of the enzyme at
both mRNA (Fig. 5) and protein level as substantiated by
higher enzyme activities and higher protein content, with a
lower apparent molecular mass, however, as shown by
Western blot (Fig. 5). The same results were obtained with
mucus-secreting HT29-RevMTX 1025 cells and entero-
cytic HT29-RevMTX1023 cells (data not shown). The ef-
fect of GalNAc-a-O-benzyl on apical glycoproteins is not
dependent on the support the cells are cultured on, as ex-
emplified by the swelling of the cells and the intracytoplas-
mic accumulation of DPP-IV also observed in treated fil-
ter-grown cells (data not shown).
The Effects of GalNAc-a-O-benzyl Are Reversible
Switching back the cells to drug-free medium after 20 d of
treatment results in a rapid reversal of the phenotype de-
scribed above: within 24 h the volume of the cells de-
creases, and in the following days apical glycoproteins re-
distribute to the apical surface (Fig. 6 e). At the same time,
mucus secretion resumes, judged by the occurrence of a
visible gel on the surface of the cell layer demonstrated by
alcian blue staining (data not shown) and immunofluores-
cence reactivity to antimucus antibodies of cell layer sec-
tions (Fig. 6 f).
NeuAca2-3Galb1-3GalNAc Is a Major Oligosaccharide 
Species Associated with Mucins and Other 
Glycoproteins from Differentiated HT-29 Cells
To characterize the oligosaccharide species associated with
Figure 1. Dose-dependent effect of GalNAc-a-O-benzyl on cell
growth, cell density, and cell volume. HT29-RevMTX1026 mucus-
secreting cells were cultured in 24-well cell culture clusters in the
absence (u) or under permanent exposure to 0.5 (r), 1 (m), or
2 mM (j) GalNAc-a-O-benzyl. Values of growth curves are the
means of five different passages. SD (data not shown) are less
than 5%. (a–d) Phase-contrast microscopy of the cell layer of (a)
control cells and cells treated with (b) 0.5, (c) 1, and (d) 2 mM
GalNAc-a-O-benzyl after 20 d in culture. Cells treated with 0.1 mM
GalNAc-a-O-benzyl were similar to control cells (data not
shown). (e and f) Light microscopy in a Malassez cell of cells
trypsinized after 20 d in culture: (e) control cells; (f) cells treated
with 2 mM GalNAc-a-O-benzyl. The volume of the cells corre-
sponding to e and f, as deduced from hematocrit and cell number,
is 1.5 6 0.1 mm3 per 106 cells in control, versus 8.5 6 0.3 mm3 per
106 cells in treated cells. Bar, 75 mm.Huet et al. Blocking Effect of GalNAc-a-O-benzyl on Glycoprotein Traffic 1315
mucins and other glycoproteins from HT-29–differenti-
ated cells, we used the lectin MAA, which reacts with
NeuAca2-3Gal-R terminal sequence and PNA, which reacts
with the O-linked T antigen (Galb1-3GalNAca1-O-Ser/Thr).
As shown in Fig. 7 via double immunofluorescence, mucus
from control HT29-RevMTX1026 cells is reactive with MAA
(Fig. 7, top panel, a–c), whereas only a small proportion of
the mucus reacts with PNA (Fig. 7, top panel, d–f). After
treatment with sialidase from Clostridium perfringens, all
the mucus is reactive with PNA (data not shown), confirm-
ing the fact that a large proportion of the mucus expresses
the NeuAca2-3Galb1-3GalNAc sequence. Because mucus
droplets are concentrated in the apical cytoplasm and do
not allow to distinguish the reactivity of brush border–
associated glycoproteins to lectins in mucus-secreting cells,
we used enterocytic HT29-RevMTX1023 cells to further
characterize the reactivity of these glycoproteins to lectins.
As shown on cryostat sections from postconfluent cells
(Fig. 7, middle panel), MAA shows a strong apical reactivity
(Fig. 7, middle panel, a), whereas PNA is unreactive (Fig. 7,
middle panel, e). After sialidase treatment, there is no
longer any reactivity to MAA (Fig. 7, middle panel, c),
whereas  PNA shows a strong apical staining (Fig. 7, middle
panel, g), thus testifying the presence of a large amount of
sialyl-T antigen linked to brush border–associated glyco-
proteins. In contrast, no basolateral labeling was observed
with MAA by confocal microscopy (Fig. 7, bottom panel),
thus indicating that sialyl-T antigen is not associated with
basolateral glycoproteins in differentiated HT-29 cells. The
association of NeuAca2-3Galb1-3GalNAca1-O-Ser/Thr with
glycoproteins in differentiated HT-29 cells was confirmed by
Western blot analysis of cell homogenates from the different
HT-29 cell populations (Fig. 8) which suggest, based on the
reactivity to MAA and PNA before and after treatment
with sialidase, that NeuAca2-3Galb1-3GalNAca1-O-Ser/
Thr sequence is associated not only to mucins, but also to a
number of glycoproteins with a molecular mass in the 80–
400 kD range. Among the glycoproteins that react with MAA
are DPP-IV, MUC1, and CEA as shown by immunoblot
analysis with MAA of these immunoprecipitated proteins
(see Fig. 10). NeuAca2-3 glycosylation of T antigen is fur-
ther supported by the observation that ST3Gal I is ex-
pressed at all stages of the culture in mucus-secreting as
well as in enterocytic HT-29 cells, as substantiated by anal-
ysis of ST3Gal I mRNA level and enzyme activity (Fig. 8).
Interestingly, no reactivity was observed by immunoblot-
ting cell homogenates with mAb B72.3 against sialyl-Tn
(data not shown) or SNA that recognizes the terminal oli-
gosaccharide species NeuAca2-6Gal (Fig. 9).
Treatment with GalNAc-a-O-benzyl Results in a 
Decreased a2,3-Sialylation of Glycoproteins
Western blot analysis of the reactivity to lectins of cell ho-
mogenates from postconfluent HT29-RevMTX1026 cells
treated with various concentrations of GalNAc-a-O-ben-
zyl shows a dose-dependent decrease of MAA-reacting
glycoproteins associated with a dose-dependent increase
Figure 2. Effects of GalNAc-a-O-benzyl on cell morphology and mucus expression in HT29-RevMTX1026 mucus-secreting cells. Cells
were cultured in the absence or under permanent exposure to 2 mM GalNAc-a-O-benzyl and then analyzed after 21 d in culture. Left
column, light microscopy of thin sections of the cell layer perpendicular to the surface of the flask. Middle column, alcian blue staining of
cryostat sections of cell layers from the same cultures, counterstained with nuclear red. Right column, indirect immunofluorescence
staining with pAb L56/C of cryostat sections of the same cell layers. (a–c) Untreated cells; (d–f), cells treated with GalNAc-a-O-benzyl.
Bars: left column (17 mm); middle and right columns (40 mm).The Journal of Cell Biology, Volume 141, 1998 1316
in PNA-reacting glycoproteins, with a maximum effect ob-
served at a drug concentration of 2 mM (data not shown).
This was further confirmed by the observation, using im-
munofluorescence, that regardless of their phenotype, the
cytoplasm of cells treated with 2 mM GalNAc-a-O-benzyl
is heavily stained with PNA, in contrast to control cells
(data not shown). Western blot analysis of immunoprecip-
itated DPP-IV, MUC1, and CEA with MAA and PNA
shows that MAA reactivity of these glycoproteins is re-
duced in cells treated with GalNAc-a-O-benzyl. Concomi-
tant to these changes, a reactivity to PNA was observed
for MUC1 and DPP-IV, but not for CEA (Fig. 10). The
changes in glycosylation are reversible upon removal of
the drug; Western blot analysis of the reactivity to lectins
of cell homogenates from cells reverted to drug-free me-
dium shows a reappearance of MAA reactivity and the
concomitant disappearance of PNA reactivity of a number
of glycoproteins in the 80–400 kD range (data not shown).
These include MUC1, DPP-IV, and CEA as shown by
Western blot analysis with lectins of the immunoprecipi-
tates of these glycoproteins (Fig. 10).
The GalNAc-a-O-benzyl–dependent Secretory Block 
Occurs beyond the cis-Golgi Compartment of the Cells
To further characterize at which level the block induced by
GalNAc-a-O-benzyl occurs, immunoprecipitates of apical
glycoproteins from control and treated cells were analyzed
Figure 3. Effect of GalNAc-
a-O-benzyl on the cellular
distribution of polarized pro-
teins in mucus-secreting HT-29
cells. Indirect immunofluores-
cence detection of polarized
proteins in frozen cryostat
sections of the cell layers from
control (left column) and 2
mM GalNAc-a-O-benzyl–
treated HT29-RevMTX1026
cells (right column) analyzed
after 21 d in culture. Sections
of the cell layers were single
labeled with antibodies against
villin (a and b), ZO1 (c and d),
glycoprotein GP120 (e and f),
DPP-IV (g and h ), MUC1
(i and j), and CEA (k and l).
Bar, 40 mm.Huet et al. Blocking Effect of GalNAc-a-O-benzyl on Glycoprotein Traffic 1317
for their sensitivity to endoglycosidase H and endoglycosi-
dase F treatment. As exemplified for DPP-IV and CEA
(Fig. 11 A), the same results were observed in treated
and control cells with both proteins being endoglycosidase
H–resistant and endoglycosidase F–sensitive, suggesting
that the block occurs after the cis-Golgi. This was further
confirmed by analysis of the biosynthesis of DPP-IV that
shows the processing of the enzyme is similar in treated
and in control cells (Fig. 11 B).
Discussion
The present results suggest that in HT-29 cells, a2,3-sialy-
lation plays a crucial role in intracellular transport of
brush border membrane–associated glycoproteins and in
mucus secretion. They rely on the exceptional conjunction
of a number of factors: (a) the availability of polarized
cells, isolated from the HT-29 cell line, expressing either
an enterocytic or a mucus-secreting differentiated pheno-
type; (b) the neoplastic nature of these cells which, as such,
show a modified pattern of protein glycosylation as com-
pared with their normal counterpart with shorter oligosac-
charide side chains (for review see Lesuffleur et al., 1994);
(c) the fact that the main sialyltransferase activities ex-
pressed in HT-29 cells catalyze the transfer of sialic acid to
the 3-position of Gal in the Galb1-3GalNAc disaccharide
sequence (Dall’Olio et al., 1993; Majuri et al., 1995; Delan-
noy et al., 1996) in contrast to most colon cancers (Sata et al.,
1991) or cell lines, including the enterocytic cell line Caco-2,
which mainly express the Galb1-4GlcNAc a2,6-sialyltrans-
ferase, ST6Gal I as reported by others (Dall’Olio et al.,
1992, 1996), and confirmed here by the reactivity to SNA
of Caco-2 glycoproteins; (d) the availability of an O-glyco-
sylation inhibitor, GalNAc-a-O-benzyl (Kuan et al., 1989;
Huang et al., 1992; Byrd et al., 1995; DiIulio and Bha-
vanandan, 1995), which enters the cells and is metabolized
into a compound that acts as a competitive inhibitor of
Galb1-3GalNAc  a-2,3-sialyltransferases (Huet et al., 1995;
Delannoy et al., 1996); and (e) the fact that, in differenti-
ated HT-29 cells, NeuAca2-3Galb1-3GalNAc-R is the
main oligosaccharide species associated not only with mu-
cins, as previously reported (Capon et al., 1992; Lesuffleur
et al., 1993; Huet et al., 1995), but also, as shown here, with
a number of glycoproteins of the brush border concom-
itantly expressed in these cells. The association of
NeuAca2-3Galb1-3GalNAc-R  to apical glycoproteins re-
Figure 4. Ultrastructural morphology and localization of DPP-IV
in control and GalNAc-a-O-benzyl–treated HT-29 mucus-secret-
ing cells. HT29-RevMTX1026 cells were analyzed after 21 d of
culture in the absence (a and b) or presence (c and d) of 2 mM
GalNAc-a-O-benzyl. (a and c) Standard transmission electron
microscopy of sections perpendicular to the bottom of the flask
showing the apical microvilli in both control and treated cells, the
accumulation of mucus droplets (M) in the apical compartment
of control cells, and the very numerous vesicles (arrow) in treated
cells. (b and d) Immunogold labeling of DPP-IV using mAb HBB
3/775/42: in control cells the gold particles are strictly restricted to
the microvilli and absent from the mucus droplets; in treated cells
the gold particles are associated with the cytoplasmic vesicles.
Similar results were obtained with MUC1 and CEA (data not
shown). Bars: (a and c) 1.2 mm; (b) 0.16 mm; (c) 0.28 mm.
Figure 5. Level of expression
of DPP-IV in GalNAc-a-O-
benzyl–treated mucus-secret-
ing HT-29 cells. Control (c)
and cells treated with 2 mM
GalNAc-a-O-benzyl (t) were
analyzed after 21 d in culture.
(A) Northern blot analysis of
DPP-IV, using villin as inter-
nal control. (B) Immunoblot
analysis, with mAb 4H3 of
DPP-IV in cell homogenates.
(C) Analysis of DPP-IV enzymatic activity in the cell homoge-
nates from control (open bar) and treated cells (solid bar); results
are the means of three different cultures corresponding to three
different passages. The apparent discrepancy between the rela-
tively discrete (1.6-fold) increase in DPP-IV activity and the dra-
matic intracellular accumulation of the enzyme (see Fig. 3, h and
Fig. 4, d) can be explained by the fact that the results refer to the
specific activity of the enzyme and that other glycoproteins also
accumulate. This discrepancy disappears when DPP-IV activity is
expressed as mU/106 cells, the values being then 25 6 1 and 150 6
6 in control and treated cells, respectively.The Journal of Cell Biology, Volume 141, 1998 1318
lies exclusively on their reactivity to MAA, and not to a
biochemical characterization that would require a huge
amount of cells to be performed. However, the reliability
of MAA characterization is validated by a recent struc-
tural characterization of carbohydrate chains of the mucus
from HT29-RevMTX1025 mucus-secreting cells (that can
be easily performed since large quantities of mucus can be
harvested daily) which has confirmed that NeuAca2-
3Galb1-3GalNAc-R is the main oligosaccharide species
associated with the mucus of these cells (Hennebicq-Reig,
Figure 6. Reversibility of the effects of GalNAc-a-O-benzyl on
cell morphology, distribution of DPP-IV, and mucus secretion.
HT29-RevMTX1026 cells were cultured until day 15 in the pres-
ence of 2 mM GalNAc-a-O-benzyl and then in drug-free me-
dium. Cultures were analyzed on day 15 (a–c), and 5 d after re-
moval of the drug: (d–f). Left column, thin sections of the cell
layer; middle column, indirect immunofluorescence detection of
DPP-IV with mAb 3/775/42; right column, indirect immunofluo-
rescence detection of mucus with pAb L56/C in sections of the
cell layer. Similar results for DPP-IV were observed as for MUC1
and CEA (data not shown). Bars: left column (16 mm); middle
and right columns (80 mm).
Figure 7. Evidence that NeuAca2-3Galb1-3GalNAca1-O-Ser/Thr
is the main oligosaccharide species associated with mucins and
apical proteins from differentiated HT-29 cells. Top panel: cryo-
stat sections of cell layers from HT-29 mucus-secreting cells
(HT29-RevMTX1026) were analyzed after 21 d in culture by dou-
ble immunofluorescence labeling with antigastric mucus Ab L56/C
followed by rhodamine-coupled Ig (a and d) and fluorescein-cou-
pled MAA (b) and PNA lectins (e). In c and f, a mixed filter for
rhodamine and fluorescein was used. (a–c) Double labeling with
Ab L56/C and MAA, showing that the totality of the mucus drop-
lets reacts with MAA; (d–f), double labeling with Ab L56/C and
PNA showing that only a small proportion of mucus droplets re-
acts with PNA. Middle panel (a–h): apical reactivity to MAA and
PNA of enterocyte-like HT-29 cells. Frozen cryostat sections
from postconfluent (day 21) HT29-RevMTX1023 cells, treated or
not treated with sialidase, were double labeled with fluorescein-
conjugated MAA (a and c) or PNA (e and g) and antibodies
against villin (b, d, f, and h ), used as an apical marker, using
rhodamine-coupled Ig as a second antibody. Note in sialidase-
treated sections, the disappearance of MAA staining (c) contrast-
ing with the appearance of an apical reactivity to PNA (g). Bot-
tom panel: confocal microscopy analysis of postconfluent HT29-
RevMTX1026 cells (day 21). A section perpendicular to the cell
layer was coimmunostained by MAA (red) and mAb TS2/16
against  b1 integrin (green). Note the absence of basolateral reac-
tivity to MAA. A similar basolateral pattern as observed with
mAb TS2/16 was obtained with mAb G1/136 against GP120 (data
not shown). Bars: top and middle panels (40 mm); bottom panel
(12 mm). Huet et al. Blocking Effect of GalNAc-a-O-benzyl on Glycoprotein Traffic 1319
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Finally, it must be noted, as demonstrated by confocal mi-
croscopy, that no MAA reactivity could be detected on the
basolateral membrane of the cells.
Based on both the sugar specificity of MAA and PNA
lectins and the results of sialidase treatment, the present
data show that in addition to mucins (i.e., in HT29-
RevMTX1026 and 1025), apical O-glycosylproteins such as
MUC1 express NeuAca2-3Galb1-3GalNAc-R terminal
sequences. This being established, four main observations
can be drawn from the experiments performed with Gal-
NAc-a-O-benzyl. First, alteration of a2,3-sialylation of
mucins and of apical O-glycosylproteins is accompanied
by their accumulation into intracytoplasmic vesicles. This
accumulation, which is most likely responsible for the dra-
matic swelling of the cells, is not restricted to O-glycosyl-
proteins, but is also observed for N-glycosylproteins such
as DPP-IV and CEA. Regarding CEA, the absence of PNA
binding in treated cells may be explained by a weak ex-
pression of the Galb1-3GalNAc sequence, not in contra-
diction with the fact that the binding of MAA is decreased.
Second, the block induced by GalNAc-a-O-benzyl occurs
after the cis-Golgi as substantiated by endoglycosidase H
resistance of apical glycoproteins and normal processing
of DPP-IV. Third, these effects are reversible upon re-
moval of the drug, resulting in a concomitant restoration
of a2,3-sialylation and resumption of the secretion of mu-
Figure 8. Top panel: Western blot analysis of the reactivity to
MAA and PNA of cell extracts from differentiated mucus-secret-
ing HT-29 cells. Cell homogenates from postconfluent HT-
29-RevMTX1026 cells were analyzed after (a) 15, (b) 20, and (c)
25 d in culture for their reactivity to MAA and PNA, without or
after desialylation of the blot with Clostridium perfringens siali-
dase. The position of the prestained molecular weight markers is
indicated on the left side of the panel. Bottom panel: expression
of ST3Gal I. Northern blot analysis of ST3Gal I mRNA in expo-
nentially growing (day 5) and postconfluent (day 20) HT29-
RevMTX1023 (A) and RevMTX1026 cells (B). The same filter
was dehybridized and stained with methylene blue for RNA
quantification; only the 28s are shown here. The histogram repre-
sents activity (expressed in nmol.mg21.h21) of ST3Gal I during
the course (from day 3 to 21) in culture of HT29-RevMTX1026
cells.
Figure 9. Compared West-
ern blot analysis with MAA
and SNA lectins of cell ho-
mogenates from postconfluent
(day 21) HT29-RevMTX1025
cells, using as a control post-
confluent (day 21) Caco-2
cells. The same quantity of
proteins (50 mg) was loaded
in each lane. The samples for
each lectin were run on the
same gel. For clarity they
have been rearranged in the
figure. Note the almost total
absence of SNA-reactive ma-
terial in HT29 as compared
with Caco-2 cells. The ab-
sence of SNA-reactivity in
HT-29 cells, contrasting with
the presence of SNA-reac-
tive apical material in Caco-2
cells, was further confirmed by immunofluorescence of cell layer
sections of both populations (data not shown).
Figure 10. Western blot
analysis with MAA and PNA
lectins of immunoprecipi-
tated DPP-IV, MUC1, and
CEA from control, GalNAc-
a-O-benzyl–treated cells and
cells reverted to drug-free
medium. DPP-IV, MUC1, and
CEA were immunoprecipi-
tated from cell homogenates
with mAbs 3/775/42, BC-2,
and 517, respectively. Note
that in control cells DPP-IV,
MUC1, and CEA react with
MAA, but not with PNA. In
treated cells, the reactivity to
MAA is decreased for DPP-
IV and abolished for MUC1
and CEA, whereas DPP-IV
and MUC1, but not CEA, show a reactivity to PNA. The changes
in treated cells are reversible upon removal of the drug.The Journal of Cell Biology, Volume 141, 1998 1320
cins and of the apical delivery of brush border–associated
glycoproteins. Fourth, these effects occur without any
modification in the morphological polarity of the cells, as
shown by the normal polarized expression of villin and ZO1,
and without modification of distribution of the basolateral
glycoprotein GP120.
How can the fact be explained that GalNAc-a-O-ben-
zyl, an O-glycosylation inhibitor (Kuan et al., 1989; Huang
et al., 1992; Byrd et al., 1995) which, in HT-29, is metabo-
lized into a compound, acts as a competitive inhibitor of
Galb1-3GalNAc a2,3-sialyltransferases (Huet et al., 1995;
Delannoy et al., 1996) may also inhibit the sialylation of
N-glycosylproteins? Recent progress in the molecular clon-
ing of sialyltransferases (for review see Harduin-Lepers
et al., 1995; Tsuji, 1996; Tsuji et al., 1996) indicates that
three different enzymes (ST3Gal I, ST3Gal II, and ST3Gal
IV), encoded by different genes, located on separate chro-
mosomes (Chang et al., 1995) are able to transfer sialic
acid residues in the 3-position of Gal onto the disaccha-
ridic Galb1-3GalNAc-R sequence. The substrate specific-
ity of ST3Gal I and ST3Gal II is strictly restricted to this
particular disaccharidic sequence (Kojima et al., 1994) but
ST3Gal IV can use both Galb1-3GalNAc and Galb1-
4GlcNAc as acceptor substrates (Kitagawa and Paulson,
1994). The competitive inhibition of ST3Gal IV by Galb1-
3GalNAc-a-O-benzyl could explain the decrease of a2,3-
sialylation of N-glycosylproteins in HT-29 cells. On the
other hand, the presence of a high concentration of the
competitive substrate (i.e., Galb1-3GalNAc-a-O-benzyl)
may also decrease the concentration of CMP-NeuAc in
the Golgi lumen and therefore can compete with the other
sialyltransferases expressed in HT-29 cells via the donor
substrate.
Whatever the mechanism leading to the decrease of
a2,3-sialylation, these results show that lack of terminal
NeuAca2-3Gal-R glycosylation is associated with a block-
ade of apical targeting of brush border membrane–associ-
ated glycoproteins and mucus secretion in HT-29 cells.
They further suggest that a2,3-sialylation could play a role
in regulating the intracellular traffic of these proteins, and
in some way, support the view by Fiedler and Simons
(1994) that “it may be that oligosaccharide side chains play
a more important role in biosynthetic traffic than hitherto
recognized”. Even if the role of glycans in the intracellular
targeting of newly synthesized lysosomal enzymes via the
mannose-6–phosphate receptor pathways was clearly dem-
onstrated in human colon adenocarcinoma cell lines (Braulke
et al., 1992), a role for glycans in the sorting machinery of
membrane proteins in polarized cells has long been ex-
cluded on the basis of experiments using inhibitors of
N-glycosylation such as tunicamycin, which blocks the
transfer of Glc3Man9GlcNAc2 from dolichol to Asn, thus
resulting in the accumulation of unprocessed proteins in
the rough ER (Green et al., 1981), or castanospermine, or
1-deoxymannojirimycin which block processing before
trimming of the oligomannose chains (Duronio et al.,
1988). Very few recent observations suggest, however, a
possible role for terminal glycans in this regulation.
Growth hormone, which is nonglycosylated and secreted
from both sides of MDCK cell layers, is secreted from the
apical side when N-glycosylated (Scheiffele et al., 1995).
The sialoglycoprotein gp114 that is expressed on the apical
membrane of MDCK cells is misglycosylated and predom-
inantly basolateral in the MDCK mutant MDCKII-RCAr
(Le Bivic et al., 1993). The O-glycosylated stalk domain is
required for apical sorting of neurotrophin receptors in
polarized MDCK cells (Yeaman et al., 1997). In addition
to these particularities that concern glycoproteins, it has
been shown that among the increasing number of vesicular
proteins presumably involved in protein sorting (Roth-
man, 1994), one of them, VIP36 (Fiedler et al., 1994), pre-
sents some homology with leguminous lectins (Fiedler and
Simons, 1994) and binds GalNAc (Fiedler and Simons,
1996). Therefore, it is conceivable that terminal NeuAca2-
3Gal glycan sequences as signals, and lectins as receptors
for these signals, could be involved in the sorting machin-
ery of glycoproteins in polarized HT-29 cells. Because the
glycosylation of both lectin-like resident Golgi proteins
and in transit glycoproteins may be affected by GalNAc-a-
O-benzyl, the precise level at which the sorting machinery
is affected needs to be elucidated.
Whether or not a2,3-sialylation is exclusively involved
in the apical sorting of glycoproteins in HT-29 cells cannot
be concluded from the present work since it was only fo-
cused on brush border membrane glycoproteins and mu-
cins. From the results obtained with Western blot, it is
clear that the effects of GalNAc-a-O-benzyl are shared by
a number of other proteins that remain to be characterized
as to their nature and localization. Nevertheless, the
present data show that a shift in the predominant glycosy-
Figure 11. (A) Sensitivity to endoglycosidase H and endoglycosi-
dase F of DPP-IV and CEA from control and GalNAc-a-O-ben-
zyl-treated HT29-RevMTX1025 cells (day 21). The same quantity
of cell homogenate (30 mg of proteins) treated as indicated was
loaded in each lane. Western blot analysis of DPP-IV and CEA
was performed with mAbs 4H3 and 517, respectively. The sam-
ples for each protein were run on the same gel in a different or-
der. For clarity they have been rearranged in the figure. (B)
Pulse-chase experiment with DPP-IV. Control and GalNAc-a-O-
benzyl–treated cells (day 21) were labeled with [35S]methionine
for 15 min followed by a chase in complete medium containing
unlabeled methionine. After the indicated periods of chase, DPP-
IV was immunoprecipitated with mAb 4H3 and immunoprecipi-
tates were subjected to SDS-PAGE.Huet et al. Blocking Effect of GalNAc-a-O-benzyl on Glycoprotein Traffic 1321
lation pattern of glycoproteins from NeuAca2-3Galb1-
3GalNAc-R to Galb1-3GalNAc-R results in what appears
as a glycoprotein traffic jam that dramatically alters their
normal delivery and also leads to cell hypertrophy.
Analysis of whether the present results uncover a more
general involvement of terminal glycans in the intracellu-
lar protein transport machinery needs to consider two
main evidences. First, there is the high polymorphism of
terminal glycans which differ from one individual to an-
other. Second, and with regard to a putative role of animal
lectins as receptors for the glycan signal (Fiedler and Si-
mons, 1994), there is the strict oligosaccharide specificity
of lectins. This implies that if the results obtained with HT-29
cells rely on a general mechanism, each cellular system,
whether from human or animal origin, is unique and only
representative of the genetic background of the individual
it originates from. With regard to normal or malignant in-
testinal cells it must be noted that there are only very few
indications in which oligosaccharide species are associated
with apical glycoproteins. The only available data concern
the observation that, in the normal adult intestine, ABH
blood group antigens are the main terminal glycans associ-
ated with the intestinal brush border hydrolases in humans
(Triadou et al., 1983; Green et al., 1988) as well as in rab-
bits (Gorvel et al., 1982). With regard to differentiated co-
lon cancer cells, the results reported here are the first ob-
servation showing that in HT-29 cells, the main terminal
oligosaccharide species associated with apical glycopro-
teins is NeuAca2-3Gal. Preliminary results obtained in the
laboratory indicate that, as in rat developing enterocytes
(Roth, 1993), the apical membrane of intestinal entero-
cytes from 10–20 gestational wk fetuses is strongly reactive
with MAA; in contrast, epithelial cells in the adult human
small intestine lack MAA reactivity (our unpublished re-
sults), differing from the situation found in the adult colon
which has been shown to express an apical reactivity to
MAA (Sata et al., 1991), but which is devoid of brush bor-
der–associated hydrolases. Therefore, the type of glycosy-
lation demonstrated in HT-29–differentiated cells likely
represents one more feature of the fetal type of differenti-
ation which is known to be associated with the malignant
phenotype (Zweibaum et al., 1991).
With regard to the oligosaccharidic individual variability
it is clear that the results obtained with HT-29 cells cannot
be extrapolated as such to other cellular systems. For ex-
ample, in Caco-2 cells, in which the main expressed sialyl-
transferase is ST6Gal I (Dall’Olio et al., 1992, 1996) Gal-
NAc-a-O-benzyl has no effect, even at much higher
concentrations (10 mM), on the morphology of the cells
and the apical polarity of brush border–associated glyco-
proteins (our unpublished results). This absence of effect
is obviously consistent with the fact that in Caco-2 cells,
apical glycoproteins such as sucrase-isomaltase or DPP-IV
most likely express NeuAca2-6, as suggested from the
SNA reactivity of Caco-2 glycoproteins and that GalNAc-
a-O-benzyl has no effect on ST6Gal I.
Finally the present results draw attention to the neces-
sity of characterizing, in each experimental system, which
oligosaccharide species is associated with the apical glyco-
proteins. This is a prerequisite for any further analysis of
the role of terminal oligosaccharides in the intracellular
traffic of apical glycoproteins. It also implies that new
strategies should be developed to specifically block the
terminal glycosylation of apical glycoproteins. One chal-
lenge is to analyze whether, for example, ABH blood
group antigens are involved in the intracellular traffic of
intestinal brush border hydrolases in humans.
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